Neurophth raises over $60M to advance gene therapies

By The Science Advisory Board staff writers

November 23, 2021 -- Neurophth Therapeutics has raised over $60 million in series C financing to advance gene therapies for ophthalmic diseases.

Neurophth is an integrated genomics medicine company whose leading investors include CMG-SDIC Capital, Sequoia Capital China, Sunshine Insurance, and China Merchant Bank International Capital.

Neurophth's lead candidate, NR082 (rAAV-ND4, NFS-01), is the first adeno-associated virus 2-based gene therapy to receive investigational new drug application approval in China, with the first patient being dosed in June 2021. NR082, a gene therapy candidate for the treatment of ND4-mediated Leber hereditary optic neuropathy, has been also granted the orphan drug designation by the U.S. Food and Drug Administration.

Neurophth's gene therapy granted orphan drug designation
Neurophth Therapeutics' lead candidate, NR082, an adeno-associated virus-based gene therapy, has been granted orphan drug designation by the U.S. Food...
Improving the CRISPR-Cas9 Workflow
Following the insights gained from past research, we fielded a survey to our expert panel of scientists to quantify how the emergence of CRISPR is impacting...

Copyright © 2021

HPLC 2022
June 18-23
San Diego, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter